Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work. Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders-Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D). Strensiq is approved in the U.S., EU, Japan and Canada, and Kanuma is approved in the U.S., EU. and Japan.